Literature DB >> 34541147

Differentiation of Human Induced Pluripotent Stem Cells (iPS Cells) and Embryonic Stem Cells (ES Cells) into Dendritic Cell (DC) Subsets.

Stephanie Sontag1,2, Malrun Förster1,2, Kristin Seré1,2, Martin Zenke1,2.   

Abstract

Induced pluripotent stem cells (iPS cells) are engineered stem cells, which exhibit properties very similar to embryonic stem cells (ES cells; Takahashi and Yamanaka, 2016). Both iPS cells and ES cells have an extraordinary self-renewal capacity and can differentiate into all cell types of our body, including hematopoietic stem/progenitor cells and dendritic cells (DC) derived thereof. This makes iPS cells particularly well suited for studying molecular mechanisms of diseases, drug discovery and regenerative therapy ( Grskovic et al., 2011 ; Bellin et al., 2012 ; Robinton and Daley, 2012). DC are the major antigen presenting cells of the immune system and thus they are key players in modulating and directing immune responses ( Merad et al., 2013 ). DC patrol peripheral and interface tissues (e.g., lung, intestine and skin) to detect invading pathogens, and upon activation they migrate to lymph nodes to activate and prime lymphocytes. DC comprise a phenotypically heterogeneous family with functionally specialized subsets (Schlitzer and Ginhoux, 2014). Generally, classical DC (cDC) and plasmacytoid DC (pDC) are distinguished, exhibiting a classical and plasma cell-like DC morphology, respectively. cDC recognize a multitude of pathogens and secrete proinflammatory cytokines upon activation, while pDC are specialized to detect intracellular pathogens and secrete type I interferons ( Merad et al., 2013 ; Schlitzer and Ginhoux, 2014). cDC are further divided into cross-presenting cDC1 and conventional cDC2, in the human system referred to as CD141+ Clec9a+ cDC1 and CD1c+ CD14- cDC2. Human pDC are characterized as CD303+ CD304+ ( Jongbloed et al., 2010 ; Joffre et al., 2012 ; Swiecki and Colonna, 2015). To investigate subset specification and function of human DC, we established a protocol to generate cDC1, cDC2 and pDC in vitro from human iPS cells (or ES cells) ( Sontag et al., 2017 ). Therefore, we differentiated iPS cells (or ES cells), via mesoderm commitment and hemato-endothelial specification, into CD43+ CD31+ hematopoietic progenitors. Subsequently, those were seeded onto inactivated OP9 stromal cells with FLT3L, SCF, GM-CSF and IL-4 or FLT3L, SCF and GM-CSF to specify cDC1 and cDC2, or cDC1 and pDC, respectively.
Copyright © 2017 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Dendritic cell differentiation; ES cells; Hematopoiesis; Hematopoietic differentiation; Human dendritic cells; iPS cells

Year:  2017        PMID: 34541147      PMCID: PMC8413509          DOI: 10.21769/BioProtoc.2419

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  27 in total

Review 1.  Transcriptional programming of the dendritic cell network.

Authors:  Gabrielle T Belz; Stephen L Nutt
Journal:  Nat Rev Immunol       Date:  2012-01-25       Impact factor: 53.106

2.  I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion.

Authors:  M Fischer; J Goldschmitt; C Peschel; J P Brakenhoff; K J Kallen; A Wollmer; J Grötzinger; S Rose-John
Journal:  Nat Biotechnol       Date:  1997-02       Impact factor: 54.908

3.  Modelling IRF8 Deficient Human Hematopoiesis and Dendritic Cell Development with Engineered iPS Cells.

Authors:  Stephanie Sontag; Malrun Förster; Jie Qin; Paul Wanek; Saskia Mitzka; Herdit M Schüler; Steffen Koschmieder; Stefan Rose-John; Kristin Seré; Martin Zenke
Journal:  Stem Cells       Date:  2017-02-01       Impact factor: 6.277

Review 4.  Induced pluripotent stem cells: the new patient?

Authors:  Milena Bellin; Maria C Marchetto; Fred H Gage; Christine L Mummery
Journal:  Nat Rev Mol Cell Biol       Date:  2012-10-04       Impact factor: 94.444

5.  Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells.

Authors:  Lionel Franz Poulin; Mariolina Salio; Emmanuel Griessinger; Fernando Anjos-Afonso; Ligia Craciun; Ji-Li Chen; Anna M Keller; Olivier Joffre; Santiago Zelenay; Emma Nye; Alain Le Moine; Florence Faure; Vincent Donckier; David Sancho; Vincenzo Cerundolo; Dominique Bonnet; Caetano Reis e Sousa
Journal:  J Exp Med       Date:  2010-05-17       Impact factor: 14.307

6.  Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

Authors:  Sarah L Jongbloed; Andrew J Kassianos; Kylie J McDonald; Georgina J Clark; Xinsheng Ju; Catherine E Angel; Chun-Jen J Chen; P Rod Dunbar; Robert B Wadley; Varinder Jeet; Annelie J E Vulink; Derek N J Hart; Kristen J Radford
Journal:  J Exp Med       Date:  2010-05-17       Impact factor: 14.307

7.  Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells.

Authors:  Su-Yi Tseng; Kevin P Nishimoto; Kathryn M Silk; Anish S Majumdar; Glenn N Dawes; Herman Waldmann; Paul J Fairchild; Jane S Lebkowski; Anita Reddy
Journal:  Regen Med       Date:  2009-07       Impact factor: 3.806

Review 8.  The promise of induced pluripotent stem cells in research and therapy.

Authors:  Daisy A Robinton; George Q Daley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

9.  Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions.

Authors:  Masakatsu D Yanagimachi; Akira Niwa; Takayuki Tanaka; Fumiko Honda-Ozaki; Seiko Nishimoto; Yuuki Murata; Takahiro Yasumi; Jun Ito; Shota Tomida; Koichi Oshima; Isao Asaka; Hiroaki Goto; Toshio Heike; Tatsutoshi Nakahata; Megumu K Saito
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

10.  Interaction of Salmonella typhimurium with dendritic cells derived from pluripotent embryonic stem cells.

Authors:  Raffaella Rossi; Christine Hale; David Goulding; Robert Andrews; Zarah Abdellah; Paul J Fairchild; Gordon Dougan
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.